DUBLIN--(BUSINESS WIRE)--The "Global Alpha Glucosidase Inhibitors Market 2022-2026" report has been added to ResearchAndMarkets.com's offering.
The alpha glucosidase inhibitors market is poised to grow by $567.96 mn during 2022-2026, accelerating at a CAGR of 2.51%
The market is driven by increase in awareness of diabetes and growing initiatives, growing awareness about benefits of alpha glucosidase inhibitors, and increasing prevalence of dumping syndrome globally.
This study identifies the growing geriatric population as one of the prime reasons driving the alpha glucosidase inhibitors market growth during the next few years. Also, availability of novel and improved alpha glucosidase inhibitors and increasing r and d on alpha glucosidase inhibitors will lead to sizable demand in the market.
The report on the alpha glucosidase inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The alpha glucosidase inhibitors market analysis includes the disease type segment and geographic landscape.
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading alpha glucosidase inhibitors market vendors. Also, the alpha glucosidase inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
Key Topics Covered:
1 Executive Summary
1.1 Market overview
2 Market Landscape
2.1 Market ecosystem
3 Market Sizing
3.1 Market definition
3.2 Market segment analysis
3.3 Market size 2021
3.4 Market outlook: Forecast for 2021-2026
4 Five Forces Analysis
4.1 Five forces summary
4.2 Bargaining power of buyers
4.3 Bargaining power of suppliers
4.4 Threat of new entrants
4.5 Threat of substitutes
4.6 Threat of rivalry
4.7 Market condition
5 Market Segmentation by Disease Type
5.1 Market segments
5.2 Comparison by Disease Type
5.3 Type 2 diabetes - Market size and forecast 2021-2026
5.4 Dumping syndrome - Market size and forecast 2021-2026
5.5 Market opportunity by Disease Type
6 Customer Landscape
6.1 Customer landscape overview
7 Geographic Landscape
7.1 Geographic segmentation
7.2 Geographic comparison
8 Drivers, Challenges, and Trends
8.1 Market drivers
8.2 Market challenges
8.3 Impact of drivers and challenges
8.4 Market trends
9 Vendor Landscape
9.1 Overview
9.2 Vendor landscape
9.3 Landscape disruption
9.4 Industry risks
10 Vendor Analysis
10.1 Vendors covered
10.2 Market positioning of vendors
- Anderson Hay and Grain Co. Inc.
- AstraZeneca Plc
- Bayer AG
- BioVision Inc.
- Border Valley Trading
- Bristol Myers Squibb Co.
- C. H. Boehringer Sohn AG and Co. KG
- Eli Lilly and Co.
- GSK Plc
- Glenmark Pharmaceuticals Ltd
- Merck KGaA
- Novartis AG
- Novo Nordisk AS
- Pfizer Inc.
- Sanofi
- Straight Healthcare
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Co. Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/8shxr4
